Detalhe da pesquisa
1.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433829
2.
Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
Acta Haematol
; 146(5): 384-390, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36917966
3.
Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.
Int J Mol Sci
; 24(3)2023 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36768545
4.
Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.
Future Oncol
; 18(24): 2661-2674, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815645
5.
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Cancer Sci
; 111(12): 4526-4539, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975869
6.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ann Hematol
; 99(5): 1063-1072, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32248251
7.
PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Eur J Haematol
; 104(6): 526-537, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32003046
8.
Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression.
Int J Mol Sci
; 21(19)2020 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32992461
9.
Prognostic impact of trisomy 21 in follicular lymphoma.
Br J Haematol
; 184(4): 570-577, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30417943
10.
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ann Hematol
; 98(7): 1703-1711, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31049648
11.
The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
Biol Blood Marrow Transplant
; 24(7): 1392-1398, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29555314
12.
PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia.
Br J Haematol
; 180(5): 705-714, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29359792
13.
IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma.
Hematol Oncol
; 36(1): 196-201, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28786198
14.
A Rare Case of Chronic Active Epstein-Barr Virus (EBV) Infection Accompanied by the Infiltration of EBV-infected CD8+ T Cells into the Muscle.
J Pediatr Hematol Oncol
; 40(3): e171-e175, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29200172
15.
Short-term administration of recombinant human erythropoietin decreases B cell number in human peripheral blood.
Transfus Apher Sci
; 57(2): 208-214, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439918
16.
Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.
Cancer Sci
; 108(8): 1556-1564, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28544233
17.
The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP.
BMC Immunol
; 18(1): 26, 2017 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28511637
18.
Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Br J Haematol
; 179(3): 449-460, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28770558
19.
Polymorphism of IL-10 receptor ß affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Hematol Oncol
; 35(4): 711-718, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27405747
20.
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ann Hematol
; 95(6): 921-9, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27044390